Gary Hattersley

Dr. Hattersley joined Nuvation Bio in 2019 following a 15-year career at Radius Health Inc, where he supported the development of its oncology and women’s health portfolio, including TYMLOS®, approved by the FDA in 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture. At Radius Health, Dr. Hattersley held roles of increasing seniority, including Chief Scientific Officer, Senior Vice President of Preclinical Development, and Vice President of Biology. Prior to Radius Health, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals, where he had responsibility for the discovery and development of novel small molecule agents for the treatment of metabolic bone diseases. He also held positions at Genetics Institute investigating the application of the bone morphogenetic proteins in musculoskeletal disease. Dr. Hattersley received a Ph.D. from St. George’s Hospital Medical School in London.